2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction. DOI
Yi‐Heng Li, Chun‐Chieh Wang, Chung‐Lieh Hung

et al.

PubMed, Journal Year: 2024, Volume and Issue: 40(2), P. 148 - 171

Published: March 1, 2024

Heart failure with preserved ejection fraction (HFpEF) is a multi-organ systemic syndrome that involves cardiac and extra-cardiac pathophysiological abnormalities. Its growing prevalence causes major public concern worldwide. HFpEF usually associated multiple comorbidities, non-cardiovascular death common in patients HFpEF. In Asia, has younger age, higher of diabetes chronic kidney disease than Western countries. A 2-step diagnostic algorithm recommended this guideline. the first step, diagnosis can be made if have symptoms and/or signs heart failure, left ventricular ≥ 50%, increased natriuretic peptide, objective evidence atrial or abnormalities raised filling pressure. If still uncertain, invasive noninvasive stress test performed second step. Comorbidities need to controlled Weight reduction for obesity supervised exercise training are For pharmacological therapy, diuretic used relieve congestion sodium-glucose cotransporter 2 inhibitor, empagliflozin dapagliflozin, improve prognosis The research on advancing at rapid pace. It expected newer modalities management could appear near future.

Language: Английский

Rethinking diuretics for congestion in acute heart failure: insight from the STRONG-HF trial DOI
Anaïs Caillard, Kamilė Čerlinskaitė‐Bajorė, Alexandre Mebazaa

et al.

European Journal of Emergency Medicine, Journal Year: 2024, Volume and Issue: 31(4), P. 231 - 233

Published: June 25, 2024

aDepartment of Anesthesia-Reanimation, Cavale Blanche Hospital bLaboratoire ORPHY EA 4324, University Brest, France cClinic Cardiac and Vascular Diseases, Institute Clinical Medicine, Faculty Vilnius University, Vilnius, Lithuania dINSERM UMR-S 942 Paris eDepartment Lariboisière Hospital, Paris, Received 22 May 2024 Accepted 24 2024. Correspondence to Anais Caillard, MD, PhD, Department 29609 Boulevard Tanguy Prigent, 29200 Tel: +332 98 34 72 84; e-mail: [email protected]

Language: Английский

Citations

3
Herzinsuffizienz: Leitlinien-Update der ESC 2023 DOI
Johann Bauersachs, Samira Soltani

Herz, Journal Year: 2023, Volume and Issue: 49(1), P. 19 - 21

Published: Nov. 14, 2023

Citations

7
Risk of readmission and death after hospitalization for worsening heart failure: Role of post‐discharge follow‐up visits in a real‐world study from the Grand Est Region of France DOI Creative Commons
Guillaume Baudry,

Ouarda Pereira,

Kévin Duarte

et al.

European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 26(2), P. 342 - 354

Published: Dec. 8, 2023

Patients who experience hospitalizations due to heart failure (HF) face a significant risk of readmission and mortality. Our objective was evaluate whether the hospitalization mortality following discharge from HF differed based on adherence outpatient follow-up (FU) protocol comprising an appointment with general practitioner (GP) within 15 days, cardiologist 2 months or both (termed combined FU).

Language: Английский

Citations

7
Diagnostic and Prognostic Value of Aminoterminal Prohormone of Brain Natriuretic Peptide in Heart Failure with Mildly Reduced Ejection Fraction Stratified by the Degree of Renal Dysfunction DOI Open Access
Tobias Schupp, Mohammad Abumayyaleh, Kathrin Weidner

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(2), P. 489 - 489

Published: Jan. 16, 2024

Limited data concerning the diagnostic and prognostic value of blood-derived biomarkers in heart failure with mildly reduced ejection fraction (HFmrEF) is available. This study investigates aminoterminal prohormone brain natriuretic peptide (NT-proBNP) patients HFmrEF, stratified by estimated glomerular filtration rate (eGFR). Consecutive HFmrEF were retrospectively included at one institution from 2016 to 2022. First, NT-proBNP for acute decompensated (ADHF) was tested. Thereafter, levels tested 30-months all-cause mortality ADHF. From a total 755 hospitalized ADHF 42%. Patients revealed higher compared without (median 5394 pg/mL vs. 1655 pg/mL; p = 0.001). able discriminate an area under curve (AUC) 0.777 (p 0.001), highest AUC eGFR ≥ 60 mL/min (AUC 0.800; no seen < 30 0.576; 0.210). > 3946 associated rates months (57.7% 34.4%; HR 2.036; 95% CI 1.423–2.912; even after multivariable adjustment (HR 1.712; 1.166–2.512; 0.006). In conclusion, increasing predicted risk preserved renal function; however, not predictive mL/min.

Language: Английский

Citations

2
2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction. DOI
Yi‐Heng Li, Chun‐Chieh Wang, Chung‐Lieh Hung

et al.

PubMed, Journal Year: 2024, Volume and Issue: 40(2), P. 148 - 171

Published: March 1, 2024

Heart failure with preserved ejection fraction (HFpEF) is a multi-organ systemic syndrome that involves cardiac and extra-cardiac pathophysiological abnormalities. Its growing prevalence causes major public concern worldwide. HFpEF usually associated multiple comorbidities, non-cardiovascular death common in patients HFpEF. In Asia, has younger age, higher of diabetes chronic kidney disease than Western countries. A 2-step diagnostic algorithm recommended this guideline. the first step, diagnosis can be made if have symptoms and/or signs heart failure, left ventricular ≥ 50%, increased natriuretic peptide, objective evidence atrial or abnormalities raised filling pressure. If still uncertain, invasive noninvasive stress test performed second step. Comorbidities need to controlled Weight reduction for obesity supervised exercise training are For pharmacological therapy, diuretic used relieve congestion sodium-glucose cotransporter 2 inhibitor, empagliflozin dapagliflozin, improve prognosis The research on advancing at rapid pace. It expected newer modalities management could appear near future.

Language: Английский

Citations

2